The test will work on the existing Truenat machines that are deployed across over 3500 PHCs/CHCs and over 1200 private labs
Molbio Diagnostics has launched the Truenat H3N2/H1N1 for differential diagnosis of the H3N2 and H1N1 virus. The test is approved by the Central Drugs Standard Control Organization (CDSCO) and can provide sample-to-result in an hour’s time. Truenat H3N2/H1N1 is the first point-of-care Real-Time PCR test that aids in the confirmatory diagnosis of Influenza infections. The test will work on the existing Truenat machines that are deployed across over 3500 PHCs/CHCs and over 1200 private labs and hospitals across India, making it possible for patients to obtain a quick diagnosis at all levels of the healthcare chain.
Molbio will continue to bring innovative solutions for better patient management and eradication of different infectious diseases.
Sriram Natarajan, CEO, Founder, and Director, Molbio Diagnostics, said, “The launch of TruenatH3N2/H1N1 further strengthens Molbio’s product portfolio by providing complete testing solutions for respiratory illnesses. The multi-disease testing capability of the Truenat platform keeps healthcare facilities prepared to combat all kinds of pandemics and disease outbreaks at early stage. Molbio will continue to bring innovative solutions for better patient management and appropriate treatment of the disease.”
Dr Chandrasekhar Nair, CTO and Director, Molbio Diagnostics, said, “It is imperative that molecular methods such as Polymerase Chain Reaction (PCR) or Real-Time PCR are used to revolutionise disease diagnosis and management. Truenat has been a game changer in this regard as a point-of-care molecular platform that offers more than 40 tests right at the point of need. The launch of the TruenatH3N2/H1N1 test is just another milestone in our respiratory diseases portfolio.”
